journal: Journal of Drug Policy Analysis

Ceased

Published from January 1, 2008 to June 1, 2021

Journal of Drug Policy Analysis

A Journal of Substance Abuse Control Policy

ISSN: 1941-2851

About this journal

Objective

The journal　Journal of Drug Policy Analysis (JDPA) has ceased publication and no longer publishes with DeGruyter Publishing.

History

One issue/year, updated continuously
ISSN: 1941-2851
Content available since 2008 (Volume 1, Issue 1)

Your Benefits

Your benefits

Interdisciplinary methodology
International editorial board
Comprehensive outlook on the subject matter
Open access publication
Ahead of print publishing

History

One issue/year, updated continuously
ISSN: 1941-2851
Content available since 2008 (Volume 1, Issue 1)

Abstracting and Indexing

Journal of Drug Policy Analysis is covered by the following services:

Baidu Scholar
Cabells Journalytics
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
EBSCO (relevant databases)
EBSCO Discovery Service
Genamics JournalSeek
Google Scholar
IBR (International Bibliography of Reviews of Scholarly Literature in the Humanities and Social Sciences)
IBZ (International Bibliography of Periodical Literature in the Humanities and Social Sciences)
Japan Science and Technology Agency (JST)
J-Gate
JournalGuide
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
ProQuest (relevant databases)
Publons
QOAM (Quality Open Access Market)
ReadCube
Reaxys
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

JDPA Manuscript Preparation Guidelines

Topics

Volume 14 Issue 1

June 2021

Publicly Available December 29, 2021

Frontmatter

Page range: i-ii

Download PDF

Articles

December 1, 2021

Did the 2018 Farm Bill’s Hemp Provisions Decriminalize Marijuana?

John J. Coleman

Page range: 1-21

Abstract

In 2014, Congress removed industrial hemp with a concentration of ≥0.3% tetrahydrocannabinol (THC) dry weight from the definition of marijuana in the federal Controlled Substances Act (CSA). Hemp production was authorized in a limited pilot program until 2018, when Congress passed the Agricultural Improvement Act (Farm Bill) that expanded the program to anyone licensed to produce hemp by the U.S. Department of Agriculture (USDA) or by a USDA-approved State or Indian tribe. Hemp’s greatest value is in two of its 80-plus molecules: cannabidiol (CBD) and THC. These molecules, present in all forms of Cannabis sativa L. (cannabis), including hemp, have medicinal and recreational uses. By removing hemp from the CSA, the Farm Bill altered the legal status of hemp’s extracts, including CBD and THC. In 2018, Epidiolex ® , the world’s first and only CBD-based medicine, was approved in the U.S. The drug was placed in Schedule V of the CSA to comply with an international drug treaty requiring control of cannabis and all its extracts. In April 2020, Epidiolex was removed from the CSA schedules. This occurred, according to the Drug Enforcement Administration (DEA), because with a THC content below 0.3%, Epidiolex no longer met the Farm Bill’s criteria as a controlled substance. This review discusses the Farm Bill’s hemp provisions and how they have affected the legal status of hemp derivatives CBD and THC. The review also discusses a loophole in the Farm Bill that decriminalizes the production of marijuana by negligent hemp farmers. In passing, we discuss how lobbying by the hemp/CBD industry influenced passage of the Farm Bill.

November 29, 2021

Don’t Let the COVID-19 Crisis Go to Waste: Breaking Through the Status Quo & Flattening the Opioid Epidemic Curve

Feler Bose, Percy Menzies, Fred Rottnek

Page range: 23-40

Abstract

The objective of the paper is to understand the impact of the COVID-19 focusing event that resulted in a distinctive response by the Federal government. The paper focuses on the rapid deregulation that occurred in the opioid use disorder treatments. We frame the narrative using primarily the economic literature on deregulation during a crisis. The temporary deregulation has significantly increased access to treatment and medications and allows for the discovering of a different equilibrium. We also suggest other deregulations that need to be considered. In this paper, we suggest that the provisional deregulations should be made permanent to improve the outcome of the patients who abuse opioids.

December 27, 2021

An Examination of Racial Disparities in Misdemeanor Marijuana Possession Arrests Following Reforms in Four U.S. Jurisdictions

Kristyn A. Jones, Darren Agboh, Meredith Patten, Preeti Chauhan

Page range: 41-53

Abstract

Using data from New York, NY; Los Angeles, CA; Prince George’s County, MD; and Louisville, KY, we examine trends in racial disparities in the enforcement of misdemeanor marijuana possessionbefore and after marijuana reforms. In these jurisdictions, we find that changes to marijuana enforcement were associated with reductions in arrest rates for Black, Hispanic, and White people, though the rate of decline varied by jurisdiction. Black people were arrested at the highest rates in relation to their proportion of the population. In three of the four jurisdictions where issuing criminal citations was an enforcement option, racial/ethnic disparities in arrest rates increased post-reforms; legalization and the option to issue a civil citation were associated with reductions in racial/ethnic disparities. Trends in this study provide policymakers with information to implement effective reforms that target racial disparities in marijuana possession arrests.

Volume 11 (2018)

Volume 10 (2017)

Volume 9 (2016)

Issue 1

Volume 8 (2015)

Issue 1

Volume 7 (2014)

Issue 1

Volume 6 (2013)

Issue 1

Volume 5 (2012)

Issue 1

Volume 4 (2011)

Issue 1

Volume 3 (2010)

Issue 1

Volume 2 (2009)

Issue 1

Volume 1 (2008)

Issue 1

CiteScore	1.2	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.246	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.075	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

More information about journal rankings

Submit

The journal　Journal of Drug Policy Analysis (JDPA) has ceased publication and no longer publishes with DeGruyter Publishing.

Editorial

The journal　Journal of Drug Policy Analysis (JDPA) has ceased publication and no longer publishes with DeGruyter Publishing.

(Deutsch)

Online ISSN: 1941-2851
Type: Journal
Language: English
Publisher: De Gruyter
First published: January 1, 2008
Last published: June 1, 2021
Publication Frequency: 1 Issue per Year
Audience: Drug policy researchers, criminologists, economists, physicians, and policy makers